Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients

Kim Lachance(Montreal Heart Institute), Simon de Denus(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Sandra Korol(Montreal Heart Institute), Geneviève Pelletier(Université Laval), Jean‐Lucien Rouleau(Montreal Heart Institute), Mark Liszkowski(Montreal Heart Institute), M. Carrier(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute)
The Pharmacogenomics Journal
July 1, 2014
10.1038/tpj.2014.29
Cited by 14

Related Papers

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k